CWM
NBIX icon

Crowley Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Crowley Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$140K – 229
2025
Q3 		$140K Hold
1,000
– – 0.11% 96
2025
Q2 		$126K Hold
1,000
– – 0.11% 97
2025
Q1 		$111K Hold
1,000
– – 0.11% 94
2024
Q4 		$137K Buy
+1,000
New +$124K 0.12% 81

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Crowley Wealth Management's NBIX Position: Q4 2025 in Review

Crowley Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 1,000 shares — an estimated $140K sold.

Crowley Wealth Management first reported a position in NBIX in Q4 2024 and held it in 4 quarters. The position peaked at $140K in Q3 2025. 730 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Crowley Wealth Management reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Crowley Wealth Management sold 1,000 Neurocrine Biosciences shares in Q4 2025, an estimated $140K.
  • Crowley Wealth Management first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 4 quarters.
  • Crowley Wealth Management's Neurocrine Biosciences position peaked at $140K in Q3 2025.
  • 730 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Crowley Wealth Management's 13F filing for Q4 2025.